肌肉特异性酪氨酸激酶（MuSK）的作用和 MuSK 型重症肌无力的奥秘。
The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.
机构信息
Neurosciences Group, Nuffield Department of Clinical Neurosciences, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
出版信息
J Anat. 2014 Jan;224(1):29-35. doi: 10.1111/joa.12034. Epub 2013 Mar 4.
Abstract
MuSK myasthenia gravis is a rare, severe autoimmune disease of the neuromuscular junction, only identified in 2001, with unclear pathogenic mechanisms. In this review we describe the clinical aspects that distinguish MuSK MG from AChR MG, review what is known about the role of MuSK in the development and function of the neuromuscular junction, and discuss the data that address how the antibodies to MuSK lead to neuromuscular transmission failure.
摘要
肌肉特异性激酶重症肌无力是一种罕见的、严重的神经肌肉接头自身免疫性疾病，仅在 2001 年被确认，其发病机制尚不清楚。在这篇综述中，我们描述了 MuSK MG 与 AChR MG 相区别的临床特征，回顾了 MuSK 在神经肌肉接头发育和功能中的作用的已知信息，并讨论了阐明针对 MuSK 的抗体如何导致神经肌肉传递失败的数据。
相似文献
1
The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.肌肉特异性酪氨酸激酶（MuSK）的作用和 MuSK 型重症肌无力的奥秘。
J Anat. 2014 Jan;224(1):29-35. doi: 10.1111/joa.12034. Epub 2013 Mar 4.
2
[Clinical features of myasthenia related with autoantibodies to muscle specific tyrosine kinase (MuSK)].与肌肉特异性酪氨酸激酶（MuSK）自身抗体相关的重症肌无力的临床特征
Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12):72-6.
3
Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.抗体效应机制在重症肌无力中的作用-神经肌肉接头的发病机制。
Autoimmunity. 2010 Aug;43(5-6):353-70. doi: 10.3109/08916930903555943.
4
[Myasthenia gravis induced by autoantibodies against MuSK].抗肌肉特异性激酶自身抗体诱发的重症肌无力
Nihon Rinsho. 2008 Jun;66(6):1149-54.
5
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.抗肌肉特异性激酶（MuSK）患者抗体破坏小鼠神经肌肉接头。
Ann Neurol. 2008 Jun;63(6):782-9. doi: 10.1002/ana.21371.
6
MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.肌肉特异性激酶（MuSK）型重症肌无力免疫球蛋白G4（IgG4）会破坏低密度脂蛋白受体相关蛋白4（LRP4）与MuSK之间的相互作用，但IgG4和IgG1 - 3均可使预先形成的不依赖聚集蛋白的乙酰胆碱受体（AChR）簇分散。
PLoS One. 2013 Nov 7;8(11):e80695. doi: 10.1371/journal.pone.0080695. eCollection 2013.
7
Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.肌肉特异性酪氨酸激酶与由其他抗体引起的重症肌无力
Neurol Clin. 2018 May;36(2):293-310. doi: 10.1016/j.ncl.2018.01.004.
8
Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.重症肌无力：自身抗体对神经肌肉结构的致病作用。
Cells. 2019 Jul 2;8(7):671. doi: 10.3390/cells8070671.
9
Agonist antibody to MuSK protects mice from MuSK myasthenia gravis.激动剂抗体对 MuSK 起保护作用，可防止 MuSK 型重症肌无力。
Proc Natl Acad Sci U S A. 2024 Sep 24;121(39):e2408324121. doi: 10.1073/pnas.2408324121. Epub 2024 Sep 17.
10
[Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis].[在乙酰胆碱受体抗体阴性重症肌无力中检测到的自身抗体]
Rinsho Byori. 2014 Mar;62(3):255-60.
引用本文的文献
1
Analysis of Pz-1, a promising therapeutic for organophosphorus poisoning from rodent plasma by liquid chromatography-tandem mass spectrometry.通过液相色谱-串联质谱法分析Pz-1，一种从啮齿动物血浆中提取的有望用于治疗有机磷中毒的药物。
J Pharm Biomed Anal. 2025 Mar 15;255:116650. doi: 10.1016/j.jpba.2024.116650. Epub 2024 Dec 26.
2
Therapeutic advances of targeting receptor tyrosine kinases in cancer.靶向治疗癌症受体酪氨酸激酶的治疗进展。
Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w.
3
A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression.一项回顾性多中心研究，研究 MuSK 型重症肌无力患者在接受和未接受一般免疫抑制治疗时的临床和血清学参数。
Front Immunol. 2024 Apr 23;15:1325171. doi: 10.3389/fimmu.2024.1325171. eCollection 2024.
4
Novel pathophysiological insights in autoimmune myasthenia gravis.自身免疫性重症肌无力的新病理生理学见解。
Curr Opin Neurol. 2022 Oct 1;35(5):586-596. doi: 10.1097/WCO.0000000000001088. Epub 2022 Aug 4.
5
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.自身免疫性神经肌肉接头疾病中的抗体治疗：肌无力危象和慢性管理的方法。
Neurotherapeutics. 2022 Apr;19(3):897-910. doi: 10.1007/s13311-022-01181-3. Epub 2022 Feb 14.
6
Clinical delineation of myasthenia gravis in the Kingdom of Bahrain.巴林王国重症肌无力的临床描述。
Neurosciences (Riyadh). 2022 Jan;27(1):16-23. doi: 10.17712/nsj.2022.1.20210096.
7
The emerging role of the sympathetic nervous system in skeletal muscle motor innervation and sarcopenia.交感神经系统在骨骼肌运动神经支配和肌肉减少症中的新作用。
Ageing Res Rev. 2021 May;67:101305. doi: 10.1016/j.arr.2021.101305. Epub 2021 Feb 18.
8
Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.重症肌无力疾病亚型中的自身免疫病理学由免疫病理学的不同机制控制。
Front Immunol. 2020 May 27;11:776. doi: 10.3389/fimmu.2020.00776. eCollection 2020.
9
Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.重症肌无力：从致病性角度看，聚焦于乙酰胆碱受体聚集、跨突触稳态和突触稳定性
Front Mol Neurosci. 2020 May 28;13:86. doi: 10.3389/fnmol.2020.00086. eCollection 2020.
10
Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit.用于治疗重症监护病房急性神经肌肉疾病的新型免疫疗法。
Curr Treat Options Neurol. 2020 Feb 13;22(3):7. doi: 10.1007/s11940-020-0616-8.
本文引用的文献
1
Congenital myasthenic syndromes: an update.先天性肌无力综合征：最新进展
Pract Neurol. 2013 Apr;13(2):80-91. doi: 10.1136/practneurol-2012-000404.
2
The search for new antigenic targets in myasthenia gravis.重症肌无力中新型抗原靶点的研究。
Ann N Y Acad Sci. 2012 Dec;1275:123-8. doi: 10.1111/j.1749-6632.2012.06833.x.
3
[Progress of myasthenia gravis: discovery of Lrp4 antibodies].[重症肌无力的进展：Lrp4抗体的发现]
Rinsho Shinkeigaku. 2012;52(11):1303-5. doi: 10.5692/clinicalneurol.52.1303.
4
Structural mechanisms of the agrin-LRP4-MuSK signaling pathway in neuromuscular junction differentiation.神经肌肉接头分化中聚集素-LRP4-MuSK 信号通路的结构机制。
Cell Mol Life Sci. 2013 Sep;70(17):3077-88. doi: 10.1007/s00018-012-1209-9. Epub 2012 Nov 22.
5
Developmental consequences of the ColQ/MuSK interactions.ColQ/MuSK 相互作用的发育后果。
Chem Biol Interact. 2013 Mar 25;203(1):287-91. doi: 10.1016/j.cbi.2012.10.006. Epub 2012 Oct 23.
6
Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses.Lrp4 是神经肌肉突触中突触前分化的逆行信号。
Nature. 2012 Sep 20;489(7416):438-42. doi: 10.1038/nature11348. Epub 2012 Aug 1.
7
Distinct roles of muscle and motoneuron LRP4 in neuromuscular junction formation.肌肉和运动神经元 LRP4 在神经肌肉接头形成中的不同作用。
Neuron. 2012 Jul 12;75(1):94-107. doi: 10.1016/j.neuron.2012.04.033.
8
Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors.肌肉特异性激酶自身抗体通过逐渐消耗突触后乙酰胆碱受体导致突触功能衰竭。
Exp Neurol. 2012 Oct;237(2):286-95. doi: 10.1016/j.expneurol.2012.06.034. Epub 2012 Jul 10.
9
Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.肌肉特异性激酶重症肌无力 IgG4 自身抗体导致小鼠严重的神经肌肉接头功能障碍。
Brain. 2012 Apr;135(Pt 4):1081-101. doi: 10.1093/brain/aws025. Epub 2012 Mar 6.
10
Signaling and aging at the neuromuscular synapse: lessons learnt from neuromuscular diseases.神经肌肉突触的信号传递和衰老：神经肌肉疾病的启示。
Curr Opin Pharmacol. 2012 Jun;12(3):340-6. doi: 10.1016/j.coph.2012.02.002. Epub 2012 Feb 23.
Zotero 插件